PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Abstract
Triple-negative breast cancer (TNBC), in which cells lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and the ERBB2 (also known as HER2) receptor, is the breast cancer subtype with the poorest outcome. No targeted therapy is available against this subtype of cancer owing to a lack of validated molecular targets. We previously reported that signaling involving MYC-an essential, pleiotropic transcription factor that...
Paper Details
Title
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Published Date
Oct 24, 2016
Journal
Volume
22
Issue
11
Pages
1321 - 1329
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History